FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Zelnick Edward J.
2. Issuer Name and Ticker or Trading Symbol

MILESTONE SCIENTIFIC INC. [ MLSS ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O MILESTONE SCIENTIFIC INC., 220 SOUTH ORANGE AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

8/22/2019
(Street)

LIVINGSTON, NJ 07039
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, Par Value $0.001  8/22/2019    A    16488  A $0.37  62370  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Zelnick Edward J.
C/O MILESTONE SCIENTIFIC INC.
220 SOUTH ORANGE AVENUE
LIVINGSTON, NJ 07039
X



Signatures
/s/ Edward Zelnick 8/29/2019
**Signature of Reporting Person Date


Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Milestone Scientific Charts.
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Milestone Scientific Charts.

Milestone Scientific Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida
Wednesday 3 April 2024 (1 month ago) • GlobeNewswire Inc.
Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.
Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call
Thursday 28 March 2024 (1 month ago) • GlobeNewswire Inc.
Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.
Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio
Wednesday 28 February 2024 (2 months ago) • GlobeNewswire Inc.
Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast
Tuesday 20 February 2024 (2 months ago) • GlobeNewswire Inc.
Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update
Tuesday 16 January 2024 (4 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Friday 12 January 2024 (4 months ago) • Edgar (US Regulatory)
Milestone Scientific Inc. Announces Closing of $3.0 Million Public Offering of Common Stock
Wednesday 13 December 2023 (5 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 13 December 2023 (5 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 12 December 2023 (5 months ago) • Edgar (US Regulatory)
Form 424B5 - Prospectus [Rule 424(b)(5)]
Tuesday 12 December 2023 (5 months ago) • Edgar (US Regulatory)